Focusing the discussion on the risks of adverse events (AEs) with patient goals in mind has the potential to improve communication between oncologists and their patients who are in first-line treatment for chronic lymphocytic leukemia (CLL), according to research published in Patient Preference and Adherence.
The investigators worked to understand further how variations in attributes impact treatment choices between oncologists and patients, as research in this area is very limited.
“These data suggest that patients and oncologists may perceive the risks and benefits associated with novel agents differently,” wrote the investigators. “Patient–oncologist communication could be enhanced through a discussion of the risks of AEs, relative to treatment outcomes, with a focus on available novel therapies.”
The greatest impact on first-line treatment preferences was observed when…